BACKGROUND: Increasingly, women with a strong family history of breast cancer are seeking genetic testing as a starting point to making significant decisions regarding management of their cancer risks. Individuals who are found to be carriers of a BRCA1 or BRCA2 mutation have a substantially elevated risk for breast cancer and are frequently faced with the decision of whether to undergo risk-reducing mastectomy. OBJECTIVE: In order to provide BRCA1/2 carriers with ongoing decision support for breast cancer risk management, a computer-based interactive decision aid was developed and tested against usual care in a randomized controlled trial. DESIGN: . Following genetic counseling, 214 female (aged 21-75 years) BRCA1/2 mutation carriers were randomized to usual care (UC; n = 114) or usual care plus decision aid (DA; n = 100) arms. UC participants received no further intervention; DA participants were sent the CD-ROM-based decision aid to view at home. MAIN OUTCOME MEASURES: The authors measured general distress, cancer-specific distress, and genetic testing-specific distress at 1-, 6-, and 12-month follow-up time points postrandomization. RESULTS: Longitudinal analyses revealed a significant longitudinal impact of the DA on cancer-specific distress (B = 5.67, z = 2.81, P = 0.005), which varied over time (DA group by time; B = -2.19, z = -2.47, P = 0.01), and on genetic testing-specific distress (B = 5.55, z = 2.46, P = 0.01), which also varied over time (DA group by time; B = -2.46, z = -2.51, P = 0.01). Individuals randomized to UC reported significantly decreased distress in the month following randomization, whereas individuals randomized to the DA maintained their postdisclosure distress over the short term. By 12 months, the overall decrease in distress between the 2 groups was similar. CONCLUSION: This report provides new insight into the long-term longitudinal effects of DAs.
RCT Entities:
BACKGROUND: Increasingly, women with a strong family history of breast cancer are seeking genetic testing as a starting point to making significant decisions regarding management of their cancer risks. Individuals who are found to be carriers of a BRCA1 or BRCA2 mutation have a substantially elevated risk for breast cancer and are frequently faced with the decision of whether to undergo risk-reducing mastectomy. OBJECTIVE: In order to provide BRCA1/2 carriers with ongoing decision support for breast cancer risk management, a computer-based interactive decision aid was developed and tested against usual care in a randomized controlled trial. DESIGN: . Following genetic counseling, 214 female (aged 21-75 years) BRCA1/2 mutation carriers were randomized to usual care (UC; n = 114) or usual care plus decision aid (DA; n = 100) arms. UC participants received no further intervention; DA participants were sent the CD-ROM-based decision aid to view at home. MAIN OUTCOME MEASURES: The authors measured general distress, cancer-specific distress, and genetic testing-specific distress at 1-, 6-, and 12-month follow-up time points postrandomization. RESULTS: Longitudinal analyses revealed a significant longitudinal impact of the DA on cancer-specific distress (B = 5.67, z = 2.81, P = 0.005), which varied over time (DA group by time; B = -2.19, z = -2.47, P = 0.01), and on genetic testing-specific distress (B = 5.55, z = 2.46, P = 0.01), which also varied over time (DA group by time; B = -2.46, z = -2.51, P = 0.01). Individuals randomized to UC reported significantly decreased distress in the month following randomization, whereas individuals randomized to the DA maintained their postdisclosure distress over the short term. By 12 months, the overall decrease in distress between the 2 groups was similar. CONCLUSION: This report provides new insight into the long-term longitudinal effects of DAs.
Authors: Marc D Schwartz; Beth N Peshkin; Kenneth P Tercyak; Kathryn L Taylor; Heiddis Valdimarsdottir Journal: Health Psychol Date: 2005-07 Impact factor: 4.267
Authors: David Cella; Chanita Hughes; Amy Peterman; Chih-Hung Chang; Beth N Peshkin; Marc D Schwartz; Lari Wenzel; Amy Lemke; Alfred C Marcus; Caryn Lerman Journal: Health Psychol Date: 2002-11 Impact factor: 4.267
Authors: S Molenaar; M A Sprangers; E J Rutgers; E J Luiten; J Mulder; P M Bossuyt; J J van Everdingen; P Oosterveld; H C de Haes Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: K Tiller; B Meiser; C Gaff; J Kirk; T Dudding; K-A Phillips; M Friedlander; K Tucker Journal: Med Decis Making Date: 2006 Jul-Aug Impact factor: 2.583
Authors: Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: K A Metcalfe; A Poll; A O'Connor; S Gershman; S Armel; A Finch; R Demsky; B Rosen; S A Narod Journal: Clin Genet Date: 2007-09 Impact factor: 4.438
Authors: Annette M O'Connor; John E Wennberg; France Legare; Hilary A Llewellyn-Thomas; Benjamin W Moulton; Karen R Sepucha; Andrea G Sodano; Jaime S King Journal: Health Aff (Millwood) Date: 2007 May-Jun Impact factor: 6.301
Authors: Mary Ann O'Brien; Timothy J Whelan; Miguel Villasis-Keever; Amiram Gafni; Cathy Charles; Robin Roberts; Susan Schiff; Wenjie Cai Journal: J Clin Oncol Date: 2009-01-05 Impact factor: 44.544
Authors: Julie O Culver; Deborah J MacDonald; Andrea A Thornton; Sharon R Sand; Marcia Grant; Deborah J Bowen; Harry Burke; Nellie Garcia; Kelly A Metcalfe; Jeffrey N Weitzel Journal: J Genet Couns Date: 2011-03-03 Impact factor: 2.537
Authors: Marc D Schwartz; Claudine Isaacs; Kristi D Graves; Elizabeth Poggi; Beth N Peshkin; Christy Gell; Clinton Finch; Scott Kelly; Kathryn L Taylor; Lauren Perley Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: Darren Mays; Tiffani A DeMarco; George Luta; Beth N Peshkin; Andrea F Patenaude; Katherine A Schneider; Judy E Garber; Kenneth P Tercyak Journal: Health Psychol Date: 2013-06-24 Impact factor: 4.267
Authors: Kenneth P Tercyak; Darren Mays; Tiffani A DeMarco; Beth N Peshkin; Heiddis B Valdimarsdottir; Katherine A Schneider; Judy E Garber; Andrea Farkas Patenaude Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07 Impact factor: 4.254
Authors: Barbara A Athens; Samantha L Caldwell; Kendall L Umstead; Philip D Connors; Ethan Brenna; Barbara B Biesecker Journal: J Genet Couns Date: 2017-03-02 Impact factor: 2.537
Authors: Suzanne C O'Neill; Darren Mays; Andrea Farkas Patenaude; Judy E Garber; Tiffani A DeMarco; Beth N Peshkin; Katherine A Schneider; Kenneth P Tercyak Journal: J Community Genet Date: 2014-08-07
Authors: Elizabeth A Schackmann; Diego F Munoz; Meredith A Mills; Sylvia K Plevritis; Allison W Kurian Journal: Fam Cancer Date: 2013-03 Impact factor: 2.375
Authors: Gillian W Hooker; Kendall L Umstead; Katie L Lewis; Laura K Koehly; Leslie G Biesecker; Barbara B Biesecker Journal: Genet Med Date: 2016-10-20 Impact factor: 8.822